MTOR and acute lymphoblastic leukemia: Hyperactivated mTOR signaling in TTLshort ALL was successfully targeted leading to significant superior leukemia free survival upon mTOR inhibition by rapamycin, and even more efficiently in combination with remission induction multi-agent chemotherapy pointing to potential benefit from combined mTOR inhibition and cytotoxic therapy for these high-risk patients.